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Epstein–Barr virus nuclear antigen 2 (EBNA2) is a transcriptional activator of viral and cellular genes involved in B cell
transformation by EBV and is targeted to EBV responsive promoters through interaction with cellular DNA binding proteins
such as RBP-Jk. To develop a conditional system in which the function of EBNA2 can be switched on and off, we have
fused the hormone binding domain of the estrogen receptor to the N- or C-terminus of EBNA2. Here we show that after
transient or stable transfer of these chimerical EBNA2 genes into human B cell lymphoma lines, transactivation of LMP1,
TP1, and TP2 promoter constructs, expression of the cell surface markers CD21 and CD23, and binding of EBNA2 to its
cellular partner RBP-Jk are dependent on the presence of estrogen. The EBNA2 fusion proteins proved to be virtually
inactive in the absence of hormone. q 1995 Academic Press, Inc.
EBNA2 plays a pivotal role in B cell transformation by EBNA2 and EBNA2–estrogen receptor fusion proteins
Epstein–Barr virus (EBV). Together with EBNA-LP it is either from three EBV BamHI-W promoters (pM780-28,
the first gene expressed in primary human B cells in- p294-6/N, and p294-6/C) or the EBV BamHI-C promoter
fected with EBV (1, 2) and acts as a transactivator of viral plus two BamHI-W promoters (p554, p554-4, and p554-3).
and cellular genes involved in growth transformation by Generation of the C-terminal fusion construct (plasmids:
the virus (3 – 14). By complementation of the P3HR1 virus p294-6/C and p554-3 encoding EBNA2/ER) was achieved
defect, EBNA2 was the first viral gene shown to be es- by introducing a BglII and EcoRI site immediately in front
sential for initiation of transformation (15, 16). of the stop codon of the open reading frame of EBNA2
Fusion of a given protein with the hormone binding by in vitro mutagenesis using the oligonucleotide: 5*-
domain of a steroid receptor can render its function de- CTGGAGAGGGCAAGGGTTTTTAGAATTCGCGCGCT-
pendent on the presence of hormone (17, 18). Using N- GATAGATCTCCCTGGATGGAGGGGCGAGGT-3*. Sub-
terminal (ER/EBNA2) or C-terminal (EBNA2/ER) EBNA2 – strate for in vitro mutagenesis was a HindIII/SacI
estrogen receptor fusion proteins for complementation fragment (EBV strain B95-8 sequence coordinates:
of the P3HR1 deletion, we were able to develop a condi- 49468–52276 (20)) cloned in Bluescript. A BamHI/EcoRI
tional transformation system for EBV and to demonstrate fragment from plasmid HE14 encompassing amino acids
that EBNA2 is required not only for initiation but also 282–595 of the human estrogen receptor (21) was ligated
for maintenance of transformation (19). Here we provide into these newly generated BglII and EcoRI sites.
evidence that the chimerical proteins in the presence of The N-terminal fusion constructs (plasmids: p294-6/
estrogen transactivate viral and cellular genes and inter- N and p554-4 encoding ER/EBNA2) were generated by
act with RBP-Jk, a cellular protein targeting EBNA2 to its inserting an EcoRI site in front of the open reading frame
response elements (EBNA2RE), as does wild-type of EBNA2 by in vitro mutagenesis of a HindIII– BamHI
EBNA2. (EBV strain B95-8 sequence coordinates: 49468–48849)
Two alternative plasmid series were used to express Bluescript subclone using the oligonucleotide: 5*-AACG
CAAGATAGAATGTAGGCATGAATTCGATGGCGGCA-
GATAAAGCAAAA-3*. The hormone binding domain of the
1 Present address: Massachusetts General Hospital, Harvard Medi- estrogen receptor was inserted into this EcoRI site ascal School, The MGH Cancer Center, Charlestown, MA.
PCR fragment using HE14 as template flanked by EcoRI2 To whom correspondence and reprint requests should be ad-
dressed. sites. The sequence of the 5* primer was 5*-GTAGTTG-
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AAT-3* and the sequence of the 3* primer 5*-GATGATGA-
ATTCGACTGTGGCAGGGAAACCCTCT-3*. This PCR
fragment included Kozak’s sequence and start codon
provided by HE14 and excluded the stop codon of HE14.
The subsequent cloning steps of the p554 derivatives
regenerated EBV strain B95-8 sequence coordinates
13944 to 55775 with the following modifications: the NotI
repeats were deleted and two BamHI-W repeats restored
using p554 (16), which carries a neomycin resistance
gene and the terminal repeats, generating p554-3 and
p554-4. For construction of p294-6/C and p294-6/N clone
pM780-28 (22) was used as a vector regenerating EBV
coordinates 39018 to 54364.
To study transactivation of the EBNA2 responsive viral
latent membrane promoters LMP1, TP1, and TP2 by
EBNA2–estrogen receptor fusion proteins, BL41/P3HR1
cells were cotransfected with EBNA2 expression vectors
encoding either a constitutively active EBNA2 (pM780-
28) (23) or the chimerical EBNA2 proteins ER/EBNA2
(p294-6/N) or EBNA2/ER (p294-6/C), together with LMP1,
TP1, or TP2 promoter luciferase reporter plasmids (24,
25). After transfection, cells were kept either in the pres-
FIG. 1. Transactivation of the LMP, TP1, and TP2 promoters byence or absence of 1 mM estradiol for 48 hr and har-
EBNA2–estrogen receptor fusion proteins is dependent on the pres-vested for measuring the luciferase activity in the ex-
ence of estrogen. BL41/P3HR1 cells were cotransfected with 10 mgtracts. As shown in Fig. 1, transactivation of the viral
ER/EBNA2, EBNA2/ER, or wild-type EBNA2 expression plasmids and
promoters by the EBNA2–estrogen receptor fusion pro- 10 mg LMP, TP1, and TP2 promoter luciferase constructs (24, 25) by
teins is dependent on the presence of estrogen. The electroporation. Immediately after transfection, 1 mM estradiol was
added where indicated. Cells were harvested for measuring luciferaseextent of transactivation by the fusion protein reached
activity 48 hr after transfection. The values present arithmetic meanthe same level of induction for the LMP1 promoter, an
values of three independent experiments. The mean basal activities ofeven higher level for the TP1 promoter, and a slightly
the LMP, TP1, and TP2 promoter luciferase constructs in the absence
lower level for the TP2 promoter as compared to wild- of EBNA2 were 5418, 1161, and 280 relative light units, respectively.
type EBNA2. The vectors driving expression of the fusion
proteins from the BamHI-C-plus two W-promoters exhib-
ited a similar activity in the transient transfection assays tance (p554-4) was stably introduced into BL41, BL41/
P3HR1, BJAB, BJAB/P3HR1, and P3HR1 cells. G418-resis-(data not shown). Estrogen did neither influence the activ-
ity of the viral promoters in EBNA2 negative cells nor the tant clones were selected in the absence of estrogen
and expression of the chimerical EBNA2 protein wasdegree of transactivation by wild-type EBNA2 (data not
shown). The viral promoters were only marginally, if at analyzed by immunofluorescence and Western blotting
with the aid of the EBNA2-specific monoclonal antibodyall, activated by the chimerical EBNA2 proteins in the
absence of estrogen (1.5- to 1.8-fold for the LMP1 and R3 (26). The transfected cells expressed the slowly mi-
grating ER/EBNA2 fusion protein (data not shown). Identi-TP2, and 2.5- to 3-fold for the TP1 promoter), indicating
that regulation of the chimerical EBNA2 proteins by estro- cally to the changes observed in conditionally trans-
formed lymphoblastoid cells after withdrawal and readdi-gen is relatively tightly controlled. Cotransfection experi-
ments of the same constructs into EBV negative BL41 tion of estrogen (19), addition of hormone to the stably
transfected cells led to an increase in ER/EBNA2 proteincells revealed a similar degree of transactivation of the
viral promoters by the chimerical proteins (data not due to positive autoregulation of the BamHI-C promoter
by EBNA2 (7, 9, 10, 13, 27) and a decrease in the electro-shown), indicating that no other viral gene products are
required for the transactivation. phoretic mobility of the protein, presumably due to phos-
phorylation (28) (data not shown). Flow cytometric analy-Since the N-terminal and C-terminal fusion protein did
not show any obvious difference in transactivation (Fig. 1) sis of the cells before and after addition of hormone
revealed a significant increase in CD21 and CD23 ex-as well as transformation (19), the following experiments
were carried out with one of both fusion proteins only pression as exemplified for the BL41-K3 and BL41/
P3HR1-9A clones in Fig. 2. Expression of CD40 was not(ER/EBNA2). To see whether ER/EBNA2 can induce the
same cell surface changes as wild-type EBNA2, an ER/ affected by the addition of estrogen. Curiously, addition
of estrogen led to retardation or an arrest of proliferationEBNA2 expression plasmid conferring neomycin resis-
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FIG. 2. CD21 and CD23, but not CD40 are induced by estrogen in cells expressing ER/EBNA2. CD21, CD23, and CD40 expression was analyzed
in BL41-K3 and BL41/P3HR1-9A cells by flow cytometry before (thin line) and after treatment with 1 mM estradiol for 48 hr (thick line). The dotted
line represents staining in the absence of the first antibody. The chimerical ER/EBNA2 protein is not expressed in all G418-resistant BL41/P3HR1-
9A cells.
of the stably transfected lymphoma cells. It is at present tains RBP-Jk as well as EBNA2 and which can be super-
shifted by anti-EBNA2 monoclonal antibody R3 (25, 34,impossible to decide whether this is an artifactual prop-
erty of the ER/EBNA2 fusion protein or an inherent activity 35). To see whether ER/EBNA2 fusion protein also binds
to RBP-Jk and whether this binding is dependent on es-of EBNA2.
EBNA2 is mediating activation of viral and cellular pro- trogen, we have performed mobility shift assays with
extracts of untreated and hormone-treated BL41/P3HR1-moters at least in part through interaction with the ubiqui-
tously expressed DNA binding protein RBP-Jk (29) which 9A cells stably expressing ER/EBNA2 using the dupli-
cated RBP-Jk binding site of the TP1 promoter as a probe.targets EBNA2 to its response elements (30–34). The
EBNA2 response element of the TP1 promoter contains As illustrated in Fig. 3, extracts of untreated cells formed
only complexes I and III with one and two binding sitestwo binding sites for RBP-Jk, which have been instrumen-
tal in elucidating the interaction of EBNA2 with RBP-Jk occupied, respectively, whereas estrogen treated cells
gave rise to an additional complex (IVE) which could be(25). Mobility shift assays using the duplicated RBP-Jk
binding site of the TP1 promoter as a probe have re- supershifted with the anti-EBNA2 monoclonal antibody
(IVE*). Complexes IVE and IVE* migrated more slowlyvealed two rapidly migrating complexes containing either
one or two RBP-Jk molecules (complex I and III) and, than the EBNA2 wild-type containing complexes IV and
IV*, in line with the different molecular weights of ER/with extracts of EBNA2 expressing cells only, an addi-
tional slowly migrating complex (complex IV), which con- EBNA2 and EBNA2 wild-type protein.
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pressing wild-type EBNA2 from regulatable promoters
(36, 37) should answer this question.
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